NICE draft guidance recommends tucatinib for advanced breast cancer
Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
Source: NHS Networks - Category: UK Health Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | HER2 | Herceptin | National Institute for Health and Clinical Excelle | UK Health | Xeloda